文献速递真菌感染艾滋病与性传播感染

坦桑尼亚和赞比亚晚期HIV感染者启动ART时隐球菌抗原筛查联合社区依从性支持的成本效果分析

Cryptococcal Meningitis Screening and Community-based Early Adherence Support in People With Advanced Human Immunodeficiency Virus Infection Starting Antiretroviral Therapy in Tanzania and Zambia: A Cost-effectiveness Analysis.
PubMed 文献 · Clin Infect Dis · 2020-01-01

基于一项随机试验(干预组1001例、标准组998例,CD4<200 cells/μL),在坦桑尼亚和赞比亚评估隐球菌抗原筛查联合4周社区依从性支持的成本效果。干预组年均费用339美元(95%CI 331-347),增量成本77美元(95%CI 66-88);每挽救一个生命年的ICER为70美元(95%CI 43-211)。结论:在资源有限地区该策略具有成本效果。

要点

  • CD4<200 cells/μL启动ART者,CrAg筛查联合依从性支持可降低全因死亡率28%。
  • 每挽救一个生命年的ICER为70美元(95%CI 43-211),成本效果良好。
  • CD4<100 cells/μL者ICER为91美元(95%CI 49-443),成本效果亦佳。

核心结论

  • 隐球菌抗原筛查联合短期依从性支持在资源有限地区具有成本效果。

研究设计与样本

  • 基于随机试验的成本效果分析,纳入CD4<200 cells/μL的HIV感染成人,在达累斯萨拉姆和卢萨卡开展。
  • 干预组1001例接受CrAg筛查加4周每周家庭访视依从性支持,标准组998例接受常规诊所照护。
  • 主要经济结局为每挽救一个生命年的卫生服务费用(ICER),以2017年美元计,采用非参数自举法和单因素确定性敏感性分析。

主要发现

  • 干预组年均每人费用339美元(95%CI 331-347),增量成本77美元(95%CI 66-88)。
  • CD4<100 cells/μL者增量成本与总体相似。
  • 全部CD4≤200 cells/μL者每挽救一个生命年的ICER为70美元(95%CI 43-211)。
  • CD4<100 cells/μL者每挽救一个生命年的ICER为91美元(95%CI 49-443)。
  • 成本效果对死亡率估计最敏感。

临床怎么用

  • 对CD4<200 cells/μL启动ART的晚期HIV感染者,可考虑CrAg筛查联合短期社区依从性支持。
  • 该策略在资源有限地区具有成本效果,可支持相关卫生决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A randomized trial demonstrated that among people living with late-stage human immunodeficiency virus (HIV) infection initiating antiretroviral therapy, screening serum for cryptococcal antigen (CrAg) combined with adherence support reduced all-cause mortality by 28%, compared with standard clinic-based care. Here, we present the cost-effectiveness. METHODS: HIV-infected adults with CD4 count <200 cells/μL were randomized to either CrAg screening plus 4 weekly home visits to provide adherence support or to standard clinic-based care in Dar es Salaam and Lusaka. The primary economic outcome was health service care cost per life-year saved as the incremental cost-effectiveness ratio (ICER), based on 2017 US dollars. We used nonparametric bootstrapping to assess uncertainties and univariate deterministic sensitivity analysis to examine the impact of individual parameters on the ICER. RESULTS: Among the intervention and standard arms, 1001 and 998 participants, respectively, were enrolled. The annual mean cost per participant in the intervention arm was US$339 (95% confidence interval [CI], $331-$347), resulting in an incremental cost of the intervention of US$77 (95% CI, $66-$88). The incremental cost was similar when analysis was restricted to persons with CD4 count <100 cells/μL. The ICER for the intervention vs standard care, per life-year saved, was US$70 (95% CI, $43-$211) for all participants with CD4 count up to 200 cells/μL and US$91 (95% CI, $49-$443) among those with CD4 counts <100 cells /μL. Cost-effectveness was most sensitive to mortality estimates. CONCLUSIONS: Screening for cryptococcal antigen combined with a short period of adherence support, is cost-effective in resource-limited settings.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Kimaro GD, Guinness L, Shiri T, et al. Cryptococcal Meningitis Screening and Community-based Early Adherence Support in People With Advanced Human Immunodeficiency Virus Infection Starting Antiretroviral Therapy in Tanzania and Zambia: A Cost-effectiveness Analysis. Clin Infect Dis. 2020. PMID: 31149704. doi:10.1093/cid/ciz453

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。